Recursion Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75629V1044
SecurityMX:RXRX / Recursion Pharmaceuticals, Inc.
Institution180 Wealth Advisors, Llc
Latest Disclosed Ownership169,682 shares
Latest Disclosed Value $ 520,924
180 Wealth Advisors, Llc reports 82.06% increase in ownership of RXRX / Recursion Pharmaceuticals, Inc.

On May 1, 2026 - 180 Wealth Advisors, Llc filed a 13F-HR form disclosing ownership of 169,682 shares of Recursion Pharmaceuticals, Inc. (MX:RXRX) valued at $520,924 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 9, 2026 disclosing 93,201 shares of Recursion Pharmaceuticals, Inc.. This represents a change in shares of 82.06% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-01 2026-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 169,682 76,481 82.06 521 36.48 0.0592
2026-01-09 2025-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 93,201 36,971 65.75 381 39.05 0.0434
2025-10-16 2025-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 56,230 16,800 42.61 274 37.69 0.0334
2025-07-31 2025-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 39,430 10,665 37.08 200 30.92 0.0278
2025-04-09 2025-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 28,765 -2,465 -7.89 152 -27.96 0.0242
2025-01-14 2024-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 31,230 5,455 21.16 211 24.85 0.0331
2024-11-01 2024-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 25,775 8,320 47.67 170 26.12 0.0267
2024-07-16 2024-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 17,455 17,455 134 0.0219
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.